There wouldn’t be many who think Gaush Meditech Ltd’s (HKG:2407) price-to-earnings (or “P/E”) ratio of 10.3x is worth a mention when the median P/E in Hong Kong is similar at about 12x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.
For example, consider that Gaush Meditech’s financial performance has been poor lately as its earnings have been in decline. One possibility is that the P/E is moderate because investors think the company might still do enough to be in line with the broader market in the near future. If not, then existing…
